Insulin resistance

Outcome · 4 studies in the Atlas

Metabolic side effect of chronic mTORC2 inhibition; observed with long-term rapamycin dosing.

Evidence at a glance

TierWhat it meansStudies
BDirect human evidence1
DMechanistic / in vitro / review2

Studies

StudyYearTierFinding
POU20132013B4 weeks of high-dose resveratrol had no effect on insulin sensitivity, blood pressure, or body composition - directly contradicting the promising rodent data that drove the original hype.
KEN20162016DA Cell Metabolism review framing mTOR as the 'grand conductor' that coordinates whole-body metabolism, tissue by tissue. Especially valuable for its clear-eyed section on WHY rapamycin causes metaboli
LAM20122012DChronic rapamycin disrupts mTORC2 as well, causing insulin resistance; lifespan extension can be uncoupled from this side effect.
NCT05835999Currently active phase 2 trial (NCT05835999) directly testing this Atlas's open dosing hypothesis: whether daily low-dose (0.5mg) versus weekly (5mg) everolimus can improve aging biomarkers and insuli

Related entities

Longevity 2mTORC1 1mTOR 1Rapamycin 1mTORC2 1Everolimus 1Resveratrol 1

Open in the Atlas explorer